The ongoing SARS-CoV-2 pandemic is a serious threat to public health worldwide and, to date, no effective treatment is available. Thus, we herein review the pharmaceutical approaches to SARS-CoV-2 infection treatment. Numerous candidate medicines that can prevent SARS-CoV-2 infection and replication have been proposed. These medicines include inhibitors of serine protease TMPRSS2 and angiotensin converting enzyme 2 (ACE2). The S protein of SARS-CoV-2 binds to the receptor in host cells. ACE2 inhibitors block TMPRSS2 and S protein priming, thus preventing SARS-CoV-2 entry to host cells. Moreover, antiviral medicines (including the nucleotide analogue remdesivir, the HIV protease inhibitors lopinavir and ritonavir, and wide-spectrum antiviral antibiotics arbidol and favipiravir) have been shown to reduce the dissemination of SARS-CoV-2 as well as morbidity and mortality associated with COVID-19.
【저자키워드】 SARS-CoV-2, combination therapy, virus-based therapy, host-based therapy, SARS-CoV-2 cell entry inhibitors, TMPRSS2, 【초록키워드】 Treatment, public health, ACE2, Antiviral, S protein, SARS-COV-2 infection, SARS-CoV-2 pandemic, Ritonavir, Remdesivir, Favipiravir, Antibiotics, HIV protease inhibitor, Replication, Medicine, morbidity and mortality, receptor, dissemination, inhibitor, nucleotide, host cells, enzyme, SARS-CoV-2 entry, priming, serine protease TMPRSS2, antiviral medicine, approach, Prevent, effective, bind, shown, include, reduce, Numerous, with COVID-19, 【제목키워드】 review, current, Potential,